GlobalData (LON: DATA) announced the acquisition of competitive intelligence solutions provider Deallus on Tuesday.
The data analytics company said the acquisition of the competitive intelligence solutions provider marks further progress in its ongoing M&A strategy.
Established 20 years ago, Deallus, which focuses on the global life sciences sector, has garnered expertise in key therapy areas such as Oncology, Neuroscience, Vaccines, Rare Diseases, Cell & Gene, and Immunology.
The integration of Deallus into GlobalData's operations is expected to enhance its relationships with major pharmaceutical brands and improve the delivery of valuable insights and services to clients in the life sciences industry.
The transaction, completed on December 31, 2024, was funded through GlobalData's recently announced debt facilities.
It is the fourth acquisition completed by GlobalData in the second half of 2024, following its acquisitions of Business Trade Media International, LinkUp, and Celent, all finalised on the same date.
Mike Danson, CEO of GlobalData, stated: “Deallus's deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders.”
GlobalData added that it will issue an update on its trading and FY24 results on January 14. It will also provide further detail on the impact of its recent M&A activity.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading and investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- XTB UK regulated by the FCA – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
